Trans-Tasman Reg Structure Should Include Third-Party Review, Industry Says
This article was originally published in The Gray Sheet
Executive Summary
Industry will push for consideration of a third-party review system in upcoming stakeholder discussions on the creation of an Australia/New Zealand joint regulatory agency, according to Brian Vale, CEO of the Medical Industry Association of Australia (MIAA)